We're pleased to share the recording of our recent webinar, "Bioanalysis of Oligonucleotide Therapeutics via Nucleic Acid Nanorobotic Platform," hosted by the Oligonucleotide Therapeutics Society in May.
In this session, our R&D Scientist, Tarin Taleb, introduces our Nucleic Acid Nanorobotics (NANs) platform, explaining how it enables sensitive, robust, and versatile bioanalysis of oligonucleotide therapeutics. The webinar covers the technology's underlying mechanism, key performance characteristics, and its potential to address some of the field's most pressing analytical challenges.
The presentation also showcases two collaborative case studies that mark an important step in translating toehold-mediated strand displacement (TMSD) from a theoretical concept into a validated bioanalytical approach. To our knowledge, these represent the first commercial assay applications driven by TMSD.
Case Study 1, conducted in collaboration with AstraZeneca's team in Sweden, demonstrates the first direct plasma detection of antisense oligonucleotides (ASOs) using TMSD. The study validates the NAN platform in mouse plasma, assessing key performance metrics including accuracy, precision, reproducibility, and dilutional linearity.
Case Study 2, completed with the Nucleic Acid Therapy Accelerator in Oxford, applies the platform to the novel abcDNA ASO chemistry. Through murine plasma and liver pharmacokinetic analysis, the study demonstrates a robust, modification-tolerant approach for the sensitive and reliable quantification of chemically modified oligonucleotides.
Together, these studies highlight how the NAN platform has evolved beyond proof of concept into a practical, high-performance solution for oligonucleotide bioanalysis.
The webinar also explores how the platform is being extended to increasingly complex applications, including siRNA quantification, brain pharmacokinetic studies, antibody oligonucleotide conjugates, and short ASOs.
The session concluded with a lively Q&A covering topics such as compatibility with diverse ASO and siRNA chemistries, tissue homogenisation strategies, cellular localisation, supported tissue types, and quantification across different biological matrices.
Thank you to everyone who joined us and contributed to the discussion. We look forward to hosting more webinars in the future.
Speaker Bio
Tarin Taleb graduated from Durham University, in 2021, with a bachelor’s degree in biomedical sciences. After one year at Cambridge Research Biochemicals she joined Nanovery in 2022. Over the past four years she has been pivotal in the development of Nanovery’s Nucleic Acid Nanorobotics (NAN) platform. Her expertise covers molecular biology, DNA nanotechnology, and assay development. She currently leads optimisation of NAN assays, integrating them with complex biological matrices, and refining buffer systems to ensure assay performance for a diverse range of oligonucleotide therapeutics.
Read also
We are a data driven company using DNA nanotechnology and AI to scale up testing of nucleic acids for powerful insights from valuable samples.